Plain-English translation of NCT07074886 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two different versions of ocrelizumab — a medication used to treat multiple sclerosis — work equally well in your body. One version is already available to patients, and the other is a new formulation being developed. The study will help doctors understand if both versions are safe and effective.
Researchers want to make sure that new, improved versions of multiple sclerosis medications work just as well as the versions patients are already using. This allows pharmaceutical companies to develop better formulations while maintaining safety and effectiveness.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new or the current version of the medication as an injection during an initial phase. After that, all participants switch to receiving the new version for the continuation phase of the study. You'll have regular clinic visits for monitoring, blood tests, and check-ins to make sure the medication is working well and is safe for you.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States